Explore Unmet Needs in 2L Treatment of HR+/HER2- Advanced Breast Cancer and the Role of the PI3K/AKT/PTEN Pathway in Endocrine Therapy Resistance

In an upcoming Live Broadcast, watch your peers discuss unmet needs in second-line treatment of HR+/HER2- advanced breast cancer, and expand on the role of the PI3K/AKT/PTEN pathway in endocrine therapy resistance.

To obtain clinical expert insights, watch the live broadcast on October 26, 2023 at 7:00 PM ET and 9:00 PM ET. To register for the event, visit https://studio.mjhassoc.com/reach/HRPOSABC.

This program is sponsored by, and the speakers are presenting on behalf of, AstraZeneca. It is being presented consistent with FDA guidelines and is not approved for continuing education credit.

©2023 AstraZeneca. All rights reserved. US-78298 Last Updated 8/23